Get the Stockscreener App
160.39
2.60%
4.07
After Hours:
162.00
1.61
+1.00%
Insmed Inc stock is traded at $160.39, with a volume of 2.70M.
It is up +2.60% in the last 24 hours and down -8.74% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$156.32
Open:
$156.66
24h Volume:
2.70M
Relative Volume:
0.90
Market Cap:
$34.21B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-25.95
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
+0.70%
1M Performance:
-8.74%
6M Performance:
+55.84%
1Y Performance:
+104.45%
1-Day Range:
$153.19
$160.95
1-Week Range:
$153.19
$164.62
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
160.39 | 33.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Breaking Down Insmed: 18 Analysts Share Their Views - Benzinga
Insmed stock price target raised to $200 by RBC on Brinsupri success - Investing.com Canada
RBC Capital Raises Price Target for Insmed (INSM) to $200 | INSM Stock News - GuruFocus
What are the risks of holding Insmed IncorporatedTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Review: Is Insmed Incorporated stock a smart retirement pick2025 Performance Recap & Consistent Growth Equity Picks - baoquankhu1.vn
Insmed Inc (INSM US): Brinsupri on High Trajectory; Multiple Readouts to Make 2026 a Pivotal Year - Smartkarma
Aug Reactions: Does Capital Growth Mortgage Investors L P Preferred Security have strong EBITDA marginsPortfolio Return Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Aug Closing: What are the risks of holding Insmed Incorporated2025 Growth vs Value & Reliable Entry Point Alerts - baoquankhu1.vn
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story - Finviz
Insmed, Inc. (NASDAQ:INSM) Short Interest Up 23.4% in December - MarketBeat
Analyst Weighs Patent Cliff Risks Against Insmed’s (INSM) Growth Story - Insider Monkey
Oak Ridge Investments LLC Sells 12,052 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Campbell & CO Investment Adviser LLC Invests $2.75 Million in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analysts’ Top Healthcare Picks: Insmed (INSM), Roche Holding AG (RHHVF) - The Globe and Mail
EULAV Asset Management Acquires Shares of 90,000 Insmed, Inc. $INSM - MarketBeat
Looking At Insmed's Recent Unusual Options Activity - Benzinga
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Nisa Investment Advisors LLC Acquires 8,261 Shares of Insmed, Inc. $INSM - MarketBeat
Aug Reactions: Can Insmed Incorporated expand into new markets2025 Price Action Summary & Short-Term High Return Strategies - baoquankhu1.vn
SG Americas Securities LLC Acquires 13,305 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
Jobs Data: What is the long term forecast for Insmed Incorporated stockJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM) - The Globe and Mail
Insmed CEO William Lewis sells $3.2 million in shares By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells $3.2 million in shares - Investing.com
Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares - MarketBeat
Insmed (BIT:1INSM) Price Target Decreased by 14.88% to 185.76 - Nasdaq
Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 19,215 Shares - TradingView — Track All Markets
Short Squeeze: How Insmed Incorporated stock performs after earningsWeekly Risk Summary & Safe Entry Zone Tips - moha.gov.vn
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - MSN
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - sharewise.com
Insmed Stock Pre-Market (+4.3%): Upbeat Analyst Day Highlights Strong BRINSUPRI™ Uptake & Pipeline - Trefis
MACD Signal: How Insmed Incorporated (IM8N) stock correlates with oil marketsTrade Entry Report & Smart Investment Allocation Insights - Bộ Nội Vụ
Rally Mode: Will Insmed Incorporated stock hit new highs in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Insmed stock soars as Brinsupri sales beat expectations by 116% - Investing.com Canada
Assessing Insmed (INSM) Valuation After Strong Multi‑Year Returns And Recent Share Price Pullback - simplywall.st
Top Pharmaceutical Stocks To Follow TodayJanuary 11th - MarketBeat
Insmed (INSM) Stock Undervalued by 54.3% Based on DCF Analysis - Intellectia AI
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? - Yahoo Finance
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance HikeLearn Why - Yahoo Finance
What risks investors should watch in Insmed Incorporated stockJuly 2025 Momentum & Low Volatility Stock Suggestions - ulpravda.ru
Tangible book value per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Jim Cramer on Insmed: "This one is worth keeping an eye on" - MSN
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 - Reuters
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):